Trellus Health
plc
("Trellus
Health" or the "Company")
Notice of
Results
Investor
Presentation
LONDON, U.K. AND NEW YORK, U.S. (16 September
2024). Trellus Health plc (AIM:
TRLS), a healthcare company delivering
innovative, scientifically validated programs and technologies that
facilitate the comprehensive management of chronic conditions,
improve health outcomes and lower the costs of care, announces that
it expects to report its interim results for the period ended 30
June 2024 on Thursday 26 September 2024.
Investor Presentation
Dr. Marla Dubinsky, CEO and
Co-Founder, and Joy Bessenger, Chief Financial
Officer, will provide a video update relating to
the interim results which will be available to view on the day
via the company
website and the Investor Meet
Company platform.
Investors can register for the
Investor Meet Company Platform and receive notifications about
Trellus Health plc here:
https://www.investormeetcompany.com/trellus-health-plc/register-investor
For
further information please contact:
|
Trellus Health plc
|
https://trellushealth.com/
|
|
Dr. Marla Dubinsky, CEO and
Co-Founder
|
Via Walbrook
PR
|
|
Joy Bessenger, CFO
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and
Broker)
|
Tel: +44 (0)20 7496
3000
|
|
Jen Boorer / James Todd / Jalini
Kalaravy
|
|
|
|
|
|
Walbrook PR
|
Tel: +44 (0)20 7933
8780 or trellus@walbrookpr.com
|
|
Paul McManus / Sam Allen / Phillip
Marriage
|
Mob: +44
(0)7980 541 893 / (0)7502 558 258/ (0)7867
984 082
|
|
|
| |
About Trellus Health plc (www.trellushealth.com)
Trellus Health (AIM: TRLS) is a
healthcare company providing value-based innovative solutions and
services for chronic condition management that prioritises improved
outcomes and member experiences while managing costs of
care.
Trellus Health integrates its
proprietary resilience-based methodology with the technology,
tools, and expert coaching and educator team to deliver Trellus
Elevate™, a whole-person technology-enhanced experience that meets
each individual's unique needs and empowers them to master their
physical and emotional health. Trellus Elevate's™ clinically proven
solutions result in relieving disease burden, building
self-management skills and promoting positive health behaviours
that improve outcomes and enables thriving in the face of a chronic
condition.
The Company's proven whole person
approach recognises the interconnectedness of various aspects of a
person's life and aims to address the whole spectrum of factors
that influence behaviour, to promote comprehensive well-being and
human flourishing in a way that aligns with value-based care.
Trellus Health's approach enables better health outcomes in a
member-centric, personalised and comprehensive holistic
solution.
The Company was founded by Mount
Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD,
both experts at treating and healing both the physical and
emotional impacts of IBD and have been innovators for whole-person
healthcare for a combined 50 years.
The Company is initially focusing on
chronic costly GI conditions that have high mental health burden,
such as inflammatory bowel disease ("IBD") which includes the
chronic incurable conditions of Crohn's Disease and ulcerative
colitis. Given the common emotional and mental health struggles
often experienced by individuals suffering from a variety of
chronic conditions, Trellus Health considers its approach to have
potential utility and demand across many conditions.
The Trellus Elevate™ program
incorporates the GRITT™ methodology and learnings on resilience
from clinical research and practice conducted at the Mount Sinai
IBD Center for more than seven years. This proprietary,
resilience-driven methodology has been scientifically validated to
demonstrate meaningful improvements in patient outcomes, 71%
reduction in Emergency Department (A&E) visits, and 94%
reduction in unplanned hospitalisations, which the directors of the
Company believe indicates the potential for significant cost
savings for healthcare payers and health systems. Patients with IBD
managed with the proprietary resilience methodology also
experienced a 49% reduction in required opioid use and a 73%
reduction in corticosteroid use 12 months following starting the
program which is a major indicator of improved health
outcomes1.
Shares in Trellus Health were
admitted to trading on AIM in May 2021, under the ticker TRLS. For
more information on Trellus Health,
visit: www.trellushealth.com
1 Source: https://www.sciencedirect.com/science/article/pii/S1542356521012258
